Status:
COMPLETED
CARE FOR ALL：an Evaluation of an Asthma QIP
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
14+ years
Phase:
PHASE4
Brief Summary
This is an evaluation on an asthma Quality Improvement Program (QIP, including GINA guideline education/training and implementation) to understand the change of physician behaviours, which leads to th...
Eligibility Criteria
Inclusion
- Participant must be 14 years of age or older at the time of signing the informed consent.
- Physician-confirmed asthma diagnosis with documented evidence of variable expiratory airflow limitation (e.g. from bronchodilator reversibility testing or other test)
- Participating patients and/or their legally authorised representative must provide signed and dated written informed consent form prior to any study specific procedures.
Exclusion
- Previous diagnosis of chronic obstructive pulmonary disease (COPD) or other clinically relevant chronic respiratory disease other than asthma
- Any significant disease or disorder (e.g. cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study
- Disease or condition other than asthma that requires treatment with systemic or oral steroids
- Participation in another clinical study with an Investigational Product administered in the last 3 months prior to Visit 1.
Key Trial Info
Start Date :
July 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 3 2024
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT05440097
Start Date
July 29 2022
End Date
September 3 2024
Last Update
January 2 2026
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, China, 100020
2
Research Site
Beijing, China, 100050
3
Research Site
Beijing, China, 100080
4
Research Site
Changchun, China, 130033